26/09/2024 – AB Science today provides an update on the microtubule program AB8939 and in particular the ability of AB8939 to generate response on MECOM rearrangement Download PDF Post navigationPreviousPrevious post:AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024NextNext post:AB Science announces the success of a 5.0 million euros capital increaseRelated PostsRevenues for the first half of 2024 and update on AB Science’s activitiesOctober 10, 2024AB Science announces the completion of settlement and delivery of its latest capital increase of 5.0 million eurosOctober 9, 2024AB Science announces a slight delay in the publication of its 2024 half-year financial reportSeptember 30, 2024AB Science announces the success of a 5.0 million euros capital increaseSeptember 30, 2024AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024September 23, 2024Positive results of the Phase 2 study evaluating masitinib in Covid-19July 8, 2024
AB Science announces the completion of settlement and delivery of its latest capital increase of 5.0 million eurosOctober 9, 2024
AB Science announces a slight delay in the publication of its 2024 half-year financial reportSeptember 30, 2024
AB Science provides an update on the development of masitinib in progressive forms of multiple sclerosis post ECTRIMS 2024September 23, 2024
